ClinicalTrials.gg
CompletedNCT00855361Updated Apr 29, 2013

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

A Phase 1 interventional study of Rabeprazole sodium in Gastroesophageal Reflux, sponsored by Janssen Research & Development, LLC. Completed at 19 sites in 4 countries. Open to participants aged Up to 44 Weeks. Per ClinicalTrials.gov, last updated 2013-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
Up to 44 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
24th of 39
69 · median 100
Started
2009
with 3 others
Phase 1
7 of 40
none open now
Registered
29th of 40
by date
Lead sponsor
2 of 40
Janssen Research & Development, LLC

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 24th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 7 in phase 1, and was the 29th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: Up to 44 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in newborns and pre-term infants.

Read the detailed description

This is a multi-center Phase I study in newborns and pre-term infants (less than 44 weeks at the time of the first dose). The drug being studied is rabeprazole sodium, the active pharmaceutical ingredient in AcipHex. This study will consist of two parts, Part 1 and Part 2. Each part will consist of three phases, a pre-treatment phase (screening of up to 7 days before the start of treatment), a treatment phase (up to 28 days) and a post treatment phase (at least 14 days, but no more than 21 days after the last dose of study drug). The maximum study length for each patient will therefore be up to 8 weeks. Patients will be monitored patients with a presumptive diagnosis of GERD and who need a feeding tube for enteral alimentation (complete or partial) in place and have been admitted to a newborn intensive care unit or step down unit. The population pharmacokinetics (PK) results together with the pharmacodynamics (ie, pHmetry) data, the safety and tolerability data from Part 1 will be assessed to determine the two dose levels to be studied in Part 2 before the start of dosing. Pharmacokinetics explores how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time. Pharmacodynamics (PD) studies the action or effects a drug has on the body. All patients in Part 1 will require pH monitoring for clinical management and undergo a 24-hour PD assessment (intraesophageal and intragastric pHmetry). At least 12 patients in Part 2 (at least 6 patients from each dose group) will require pH monitoring and undergo the same PD assessment as patients in Part 1. Patients participating in the pHmetry assessment must be in need of this assessment for their clinical management in the opinion of the Principal Investigator. The intraesophageal and intragastric 24-hour pH PD assessment in both Part 1 and Part 2 will be performed at baseline (Day -1) and after the first dose (Day 1) and fifth dose (Day 5). Sampling for single dose blood level PK evaluations will be performed post-dose on Day 1. Sampling blood level evaluations at the presumed steady-state during multiple dosing will be performed on Day 5. Patients' safety will be monitored throughout the study. At the end of the study, or if any patient prematurely discontinues his/her participation in the study, a safety evaluation will be performed at least 14 days, but no more than 21 days, after the final rabeprazole sodium dose. During the course of the study, after consent each patient will have medical history, a physical, length, weight, vital signs, blood chemistry, and urinalysis. Safety from baseline to the End of Study visit (post-treatment phase) will be evaluated by examining incidence, severity and relationship to the study drug and type of Adverse Events (AEs), urinalysis, physical examination and vital signs. Patients will receive rabeprazole sodium as a single daily dose for up to 28 consecutive days. Patients participating in Part 1 will receive 1.0 mg rabeprazole sodium administered by a nasogastric tube. After four patients complete Part 1, their rabeprazole plasma levels will be assessed and the dose may be increased to 2.0 mg rabeprazole sodium. The population PK results, together with the PD (ie, pHmetry) data, safety and tolerability data from Part 1 will be assessed to determine 2 doses in Part 2.

03

Conditions studied

  • Gastroesophageal Reflux

Keywords

  • Gastroesophageal Reflux
  • Erosive Gastroesophageal Reflux Disease
  • Ulcerative Gastroesophageal Reflux Disease
  • Endoscopy
  • Pediatrics
  • GERD
  • Rabeprazole, Rabeprazole sodium
  • AcipHex
04

Who can participate

Ages eligible
Up to 44 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must need a feeding tube in place for enteral alimentation (complete or partial) and be in a neonatal intensive care unit or step down unit
  • Patients participating in the pHmetry assessment must be in need of this assessment
  • New born, neonate or pre-term infants less than 44 weeks with a minimum weight of 0.8 kg and with a presumptive diagnosis of GERD
  • Patients who have been treated with, or are currently receiving a proton pump inhibitor (PPI), H2-blockers or antacids
  • Patients should be generally healthy, other than for the presence of GERD.

Exclusion criteria

Exclusion Criteria:

  • A history of or current medical illness (excluding GERD, asthma, reactive airway disease or cystic fibrosis-dependant GERD)
  • Continuous drip tube feeding with formula or breast milk
  • Patients whose mothers are taking PPIs and who are pumping breast milk to be fed to their infants
  • Continuous positive airway pressure (CPAP) delivered via nasal prong or oral mask
  • Serum concentrations of hepatic transaminases > 3-fold higher than the for age creatinine values = 106 micromoles/L
  • Clinically relevant abnormal laboratory values
  • Treatment with full therapeutic doses of sucralfate or any medication that affects gastrointestinal motility such as baclofen, erythromycin, metoclopramide, cisapride, or domperidone
  • A history of allergy or sensitivity to PPIs or to their inactive ingredients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Rabeprazole sodium

    Drug: Rabeprazole sodium

Interventions

  • One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.

06

What researchers measure

Primary outcomes

  1. Rabeprazole plasma concentrations (Parts 1 and 2)

    Time frame: Up to Day 5

  2. Thioether metabolite plasma concentrations (Parts 1 and 2)

    Time frame: Up to Day 5

  3. The change from baseline in intraesophageal H+ concentration (Parts 1 and 2)

    Time frame: Baseline, Day 5

  4. The change from baseline in intragastric H+ concentration (Parts 1 and 2)

    Time frame: Baseline, Day 5

Secondary outcomes

  1. The number of patients with adverse events as a measure of safety and tolerability

    Time frame: Approximately 8 weeks

07

Study locations

19 sites
  • Orange, California, United States
  • Washington, District of Columbia, United States
  • Augusta, Georgia, United States
  • Maywood, Illinois, United States
  • Louisville, Kentucky, United States
  • Shreveport, Louisiana, United States
  • Lansing, Michigan, United States
  • Omaha, Nebraska, United States
  • Brooklyn, New York, United States
  • Toledo, Ohio, United States
  • Aachen, Germany
  • Bydgoszcz, Poland
  • Lublin Poland, Poland
  • Odz, Poland
  • Poznan N/A, Poland
  • Barnsley N/A, United Kingdom
  • Manchester, United Kingdom
  • Preston, United Kingdom
  • Sheffield, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2009
First posted
Mar 4, 2009
Start
Jul 2009
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Apr 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00855361
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 4, 2009
Start date
Jul 2009
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Apr 29, 2013

Study contacts

Janssen Research & Development, LLC C. Clinical Trial
study director · Janssen Research & Development, LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion